A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)

NCT00193713 Phase 3 COMPLETED

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Details

Lead sponsor	Solvay Pharmaceuticals
Phase	Phase 3
Status	COMPLETED
Start date	2005-05
Completion	2006-11

Conditions

• Schizophrenia

Interventions

• bifeprunox